XinKainuo Medical Secures Nearly RMB 100 Million Series B Financing to Advance Dual Focus on Neurovascular and Peripheral Interventions

VCBeat learned at the first opportunity that,Recently, Skynor MedicalMedicalOfficial AnnouncementCompletednearly 100 million yuanBround of financing,This round of financing was led by Zeyue Capital, with participation from Chuangban Investment and existing shareholder Anlong Fund.Dianshi Capital served as the exclusive financial advisor.

This round of financing will be primarily used for new product development, clinical trials, market promotion, and corporate operations, accelerating the regulatory approval and localization of Skynor Medical’s portfolio of over 15 products. This will empower the company to strengthen its presence in the neurointerventional and peripheral intervention markets, establishing it as a comprehensive platform company with a complete product lineup.

Skynor Medical, established in 2014 and located in the Shanghai International Medical Zone, specializes in the research and development of high-end minimally invasive vascular interventional products. With two major product lines in neurointerventional and peripheral interventional fields, the company is positioned as a platform-focused enterprise dedicated to these areas, providing comprehensive treatment solutions for patients with stroke and peripheral arterial/venous vascular diseases.

Skynor Medical has achieved rapid development since its establishment, with highly efficient R&D capabilities. The company has filed 28 patent applications, and multiple products are currently in the registration application stage.

China is one of the countries with high exposure levels to stroke risk factors globally, with a prevalence rate of 1.5%. According to an analysis report published in *The Lancet Neurology*, there were 13.7 million new cases of stroke worldwide in 2016, of which China accounted for 40%; globally, there were 5.5 million deaths from stroke, with China accounting for one-third. Each year, more than 3 million people suffer from acute ischemic stroke, and 1.8 million patients die from stroke.

The most common cause of stroke is the presence of small emboli on the inner walls of cerebral blood vessels, which detach and lead to arterial embolism, resulting in ischemic stroke.；It may also be caused by hemorrhage from cerebral blood vessels or thrombi, resulting in hemorrhagic stroke.85% of strokes are ischemic strokes, and vascular recanalization with reperfusion is currently the optimal treatment modality.，Including intravenous thrombolysis and arterial thrombectomy.In 2015, China and the United States updated their guidelines for the management of ischemic stroke.Stent retriever thrombectomy was elevated to the highest level of recommendation and listed by the Cleveland Clinic as“"Top 10 Medical Technology Innovations of 2016"

Skynor Medical has initially established a relatively comprehensive portfolio of neurointerventional product solutions. For ischemic stroke, the company’s most advanced products include thrombectomy devices and intracranial balloon dilation catheters. Access products encompass distal access catheters, microcatheters, and balloon guide catheters. Products for hemorrhagic stroke, such as intracranial flow diverters and intracranial aneurysm stents, are also being rapidly developed.The aforementioned ischemia-related products and access-related products are expected to receive certification in the first half of 2021.

On the other hand, the incidence of peripheral vascular disease remains high, while treatment rates are relatively low. China currently has up to 40 million patients with arteriosclerosis obliterans of the lower extremities, and the incidence of other arterial and venous diseases is continuously rising due to changes in lifestyle and work habits. According to Frost & Sullivan data, the market size of peripheral vascular interventional medical devices in China grew from RMB 1.7 billion in 2013 to RMB 3.01 billion in 2017, representing a compound annual growth rate (CAGR) of 15.4%. The market is expected to reach RMB 7.12 billion by 2022, with a CAGR of 18.8% from 2018 to 2022, indicating rapid development.

Among Skynor Medical's peripheral interventional products, its independently developed next-generation peripheral vascular stent is undergoing multicenter controlled clinical trials, with preliminary clinical results demonstrating excellent performance. Several other interventional products,Peripheral Balloon Dilatation CatheterNMPA Certified, PTA Balloon Dilatation Catheter is expected in 2021YearFebruaryCertified.

In terms of the team, R&D personnel account for 80% of the company's total workforce, with over 15 years of experience in the field of neurovascular and peripheral interventions. As the founder of Skynor Medical, Zhao Zhenxin boasts an impressive background. He previously served as Co-founder and Vice President of Technology at Peijia Medical (HK09996), where he led the development of multiple innovative interventional devices, including the TaurusOne transcatheter aortic valve. This product received special approval as an innovative medical device from the China National Medical Products Administration (NMPA) and successfully completed domestic multicenter clinical trials, demonstrating outstanding follow-up efficacy.

Skynor Medical aggregates high-quality industrial shareholder resources to accelerate the commercialization of its products. In 2018, Sinopharm Capital completed Series A investment in Skynor Medical. Leveraging the platform advantages of the Sinopharm Group, it provided post-investment value-added services across three dimensions—team building, regulatory registration, and sales—thereby achieving strategic synergy.

SkynorMedicalZhao Zhenxin, founder ofstated: “We extend our gratitude to both new and existing shareholders for their support of the company’s development. Skynor Medical is a technology-driven medical device company. We believe that only products endorsed by physicians, capable of effectively and reliably alleviating patients’ suffering from diseases, can be deemed ‘good products.’ This philosophy has been consistently upheld by Skynor Medical in its product development.”

Lü Xiaoxiang, Founding Partner of Zeyue CapitalOpinion:“Domestic substitution accompanied by market expansion is the future development logic of the neurointerventional sector, and companies with continuous technological innovation and commercialization capabilities will have the opportunity to become industry leaders. Skynor MedicalHigh-quality, high-tech products with rapid and efficient R&D and registration capabilities, Aggregating High-Quality IndustriesResources, and excellentCommercialization ImplementationStrong capabilities, leading competitiveness, and a promising future.”

Wu Yuepeng, Partner at Anlong Fundstated: “In the field of neurointervention, there are opportunities for strategic deployment in areas such as intracranial flow diverter stents, intracranial aneurysm stents, carotid artery stents, neuromodulation, and neurophysiology products. We believe that China will inevitably see the emergence of successive waves of technology-driven domestic medical device leaders, and Anlong Fund aims to serve as an early-stage enabler for these companies.”

Yan Di, Head of Healthcare at Chuangban Investment“It stated: ‘With the rise of the domestic neurointerventional device industry and the acceleration of import substitution, platform-based companies represented by Skynor Medical will usher in significant opportunities for robust growth. The Skynor team boasts strong backgrounds and technical prowess, coupled with a profound understanding of commercialization—a rare and valuable combination.’”

Zeyue CapitalCo-founded by CEOs of multinational pharmaceutical companies and successful scientist-entrepreneurs from Silicon Valley, the firm is an investment institution focused on the healthcare sector. Leveraging profound insights into China’s healthcare landscape and medical reform trends, the founders integrate industrial resources across R&D, manufacturing, and marketing to identify startups with a “China perspective” and sustainable growth potential globally, making investment decisions grounded in long-term value creation. Currently, Zeyue’s portfolio covers high-quality projects in biopharmaceuticals, medical devices, and healthcare services.

Anlong FundAs professional investors in the life sciences and healthcare sectors, we focus on pharmaceuticals, medical devices, healthcare services, and life sciences. Our team brings together expertise in scientific research, multinational corporations, entrepreneurship, and investment, representing a perfect blend of overseas education and local experience, with a strong professional background in life sciences and healthcare. We maintain close collaboration with the Chinese Academy of Sciences and possess an extensive resource platform.

Chuangban InvestmentEstablished in 2015, it is committed to providing comprehensive entrepreneurial services, including an integrated platform for project showcases, financing matchmaking, partner seeking, incubation services, recruitment and job hunting, event announcements, and entrepreneurial networking. It has previously invested in projects such as Mingyue Medical, vipSing, and Qutoutiao.